Other
Accounts payable and other current liabilities
Neurocrine Biosciences Accounts payable and other current liabilities decreased by 118.7% to -$14.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 376.7%, from -$3.00M to -$14.30M. Over 3 years (FY 2021 to FY 2025), Accounts payable and other current liabilities shows an upward trend with a 41.3% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests the company is effectively utilizing supplier credit to preserve cash, while a decrease indicates faster payment cycles.
Detailed definition
Reflects the net change in obligations to suppliers and other accrued expenses that have been incurred but not yet paid....
Peer comparison
A standard working capital metric used to evaluate cash management strategies across all sectors.
Metric ID:
other_increase_decrease_in_accounts_payable_and_accrued__ecb401Historical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.00M | $8.70M | $19.10M | $11.50M | $32.70M | $32.80M | $37.60M | $6.70M | $16.20M | $124.40M | -$18.60M | -$59.50M | $44.20M | $77.30M | -$3.00M | $30.90M | $55.80M | $76.50M | -$14.30M |
| QoQ Change | — | -51.7% | +119.5% | -39.8% | +184.3% | +0.3% | +14.6% | -82.2% | +141.8% | +667.9% | -115.0% | -219.9% | +174.3% | +74.9% | -103.9% | >999% | +80.6% | +37.1% | -118.7% |
| YoY Change | — | — | — | — | +81.7% | +277.0% | +96.9% | -41.7% | -50.5% | +279.3% | -377.6% | -467.3% | -64.5% | — | +83.9% | +151.9% | +26.2% | -1.0% | -376.7% |
Range-$59.50M – $124.40M
CAGR-5.0%
Avg YoY Growth-27.3%
Median YoY Growth+12.6%
Accounts payable and other current liabilities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accounts payable and other current liabilities?
- Neurocrine Biosciences (NBIX) reported accounts payable and other current liabilities of -$14.30M in Q1 2026.
- How has Neurocrine Biosciences's accounts payable and other current liabilities changed year-over-year?
- Neurocrine Biosciences's accounts payable and other current liabilities decreased by 376.7% year-over-year, from -$3.00M to -$14.30M.
- What is the long-term trend for Neurocrine Biosciences's accounts payable and other current liabilities?
- Over 3 years (2021 to 2025), Neurocrine Biosciences's accounts payable and other current liabilities has grown at a 41.3% compound annual growth rate (CAGR), from $56.80M to $160.20M.
- What does accounts payable and other current liabilities mean?
- The change in the amount the company owes to suppliers and for other unpaid expenses.